COMPASS Pathways Stock (NASDAQ:CMPS)
Previous Close
$5.33
52W Range
$2.25 - $7.08
50D Avg
$5.88
200D Avg
$4.41
Market Cap
$517.45M
Avg Vol (3M)
$1.87M
Beta
1.94
Div Yield
-
CMPS Company Profile
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.